[Substance P-antagonists as a new class of antidepressant drugs].
Lieb
K
K
Abteilung Psychiatrie und Psychotherapie, Universitätsklinikum Freiburg, Germany. klaus_lieb@psyallg.ukl.uni-freiburg.de
Herpfer
I
I
Fiebich
B L
BL
Berger
M
M
D000818:Animals; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077608:Aprepitant; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D051379:Mice; D018345:Mice, Knockout; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use*; D064729:Neurokinin-1 Receptor Antagonists; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D013373:Substance P / Q000037:antagonists & inhibitors*; D013997:Time Factors
D000928:Antidepressive Agents; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D010919:Placebos; D000077608:Aprepitant; D013373:Substance P